At the close of Tuesday’s trading, Biophytis SA (NASDAQ: BPTS) shares reached a high of $14.28 and dropped to a low of $12.02. There were 8799 shares of Biophytis stock moved during the trading session, representing a decline of -82.1% from the average session volume of 49.17K shares. At the close of trading on Wednesday, BPTS stock was at $13.92. The correction of false news brings the BPTS stock price higher.
What happened?
The Biophytis SA clinical-stage biotechnology company is dedicated to developing therapies that target slowing the degenerative processes associated with aging and improving functional outcomes in COVID-19 patients suffering from severe respiratory failure.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
One of the top drug candidates for BPTS is Sarconeos (BIO101). A Phase 2 clinical trial is being carried out in the United States and Europe to evaluate the effectiveness of the orally-administered, small molecule (SARA-INT) in the treatment of sarcopenia.
An untrue report regarding the status of BioPhytis’ Sarconeos study (BIO101) in COVID-19 in Brazil has been brought to BioPhytis’ attention. Unknown to Biophytis, a WBOC article was released on April 12, 2021. Unknown sources released the press release without knowledge of BPTS, causing it to be misleading.
Measures taken by BPTS:
BioPhytis (BPTS) said that the press release about the COVA study in Brazil was not written or released by it. A report has been made by BPTS to the proper authorities and WBOC regarding this instance. Also, BPTS expressed that under no circumstances does it assume responsibility for any loss or damage that arises out of or in connection with this press release.
